COYA Stock — Coya Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$4.42

Market cap

$106.26M

Price action

19 metrics

Price change (1W)

-10.5%

Price change (30D)

+1.8%

Price change (3M)

-4.7%

Price change (6M)

-3.8%

Price change (YTD)

-22.2%

Price change (1Y)

-31.3%

Trailing year

Price change (5Y)

—

52-week high

$7.36

52-week low

$3.78

Change from 52-week high

-38.7%

Change from 52-week low

+19.3%

Annualized volatility

64.5%

Beta

1.4

RSI (14D)

42.7

Price vs SMA 50

-7.0%

Price vs SMA 200

-7.6%

Avg volume (3M)

187,316

Relative volume

0.5

Average dollar volume

$918,497

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

23.46M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

13.3×

reciprocal yield 7.5%

P / book

2.5

reciprocal yield 40.7%

FCF yield

—

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-20.4%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-06-02

Profitability

9 metrics

Gross margin

—

Operating margin

-288.7%

Trailing 12 months

Net margin

-270.2%

Gross profit (TTM)

—

Operating profit (TTM)

−$23.15M

Net income (TTM)

−$21.67M

Trailing 12 months

Diluted EPS (TTM)

$-1.07

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$1.41

Growth

11 metrics

Revenue growth YoY

+49.0%

Year over year

Net income growth YoY

—

Revenue (TTM)

$8.02M

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+40.3%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-50.1%

Return on assets

-45.8%

Debt / equity

—

Current ratio

13.4

EBITDA (TTM)

—

Free cash flow (TTM)

—

Quick ratio

13.4

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$43.18M

Latest balance sheet

Cash & equivalents

$43.18M

Total assets

$47.31M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$15.72M

Capital expenditures (TTM)

—

R&D (TTM)

$16.98M

SG&A (TTM)

—

Stock compensation (TTM)

$5.31M

R&D / revenue

211.8%

Stock compensation / revenue

66.3%

Ownership (13F)

3 metrics

13F filers

55

13F filer change QoQ

-2

Institutional ownership

33.4%

Short interest

3 metrics

Short interest

4.5%

Latest settlement · 7.8 days to cover

Days to cover

7.8d

Short-squeeze score

66 / 100

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

COYA · Coya Therapeutics, Inc.

COYA metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search